SCHEDULE: Walters Group Adjusts Zentalis Stake

William T. Walters, The Walters Group, and Susan B. Walters report a combined beneficial ownership of 18.8% in Zentalis Pharmaceuticals, Inc., reflecting shared voting and dispositive power.

Summary

• This filing is an amendment to Schedule 13G, reporting changes in beneficial ownership of Zentalis Pharmaceuticals, Inc. common stock.
• The reporting persons are William T. Walters, The Walters Group (TWG), and Susan B. Walters.
• TWG directly owns the shares, while William T. Walters and Susan B. Walters may be deemed to share voting and dispositive power.
• The total number of shares beneficially owned by the reporting persons is 17,844,973.
• This represents 18.8% of the class of securities outstanding.
• The outstanding shares of common stock were reported as 94,668,568 as of August 14, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a change in beneficial ownership without new strategic information or financial performance updates.

Positives

• The reporting persons collectively hold a significant stake (18.8%) in Zentalis Pharmaceuticals, Inc., indicating substantial investor confidence.
• The filing clarifies the ownership structure and shared voting/dispositive power among the reporting persons.

Negatives

• The filing does not provide any new financial performance data or strategic updates for Zentalis Pharmaceuticals, Inc.
• The nature of the 'change' in beneficial ownership is not detailed, only the resulting ownership percentage.

Risks

• Concentration of ownership among a few reporting persons could potentially influence corporate control or strategic decisions, though the filing states these shares were not acquired for the purpose of changing control.
• Any future disposition of these shares by the reporting persons could impact the stock price.

Future Outlook

No forward-looking statements or guidance are provided in this Schedule 13G filing.

Management Comments

• Each Reporting Person disclaims beneficial ownership with respect to any Shares other than the Shares owned directly by such Reporting Person (if any).
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant shareholders to report their holdings. This filing indicates a substantial, ongoing investment in the biotechnology sector by the Walters entities.

Stakeholder Impact

• Shareholders: The filing clarifies the ownership structure, which may be of interest to other shareholders. A significant stake held by a few entities could imply stability or potential for influence.
• Management: The reporting persons' significant stake and shared voting power may influence board composition or strategic direction discussions.

Next Steps

• The reporting persons will continue to monitor their beneficial ownership in Zentalis Pharmaceuticals, Inc. and may file amendments to this Schedule 13G as required by SEC regulations.

Key Dates

Keywords

Zentalis Pharmaceuticals, Schedule 13G, Beneficial Ownership, Walters William T, Walters Group, Susan B. Walters, Common Stock, Ownership Stake